{"title":"In vitro activity of cefixime, a new oral cephalosporin.","authors":"R J Fass, V L Helsel","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The in vitro activities of cefixime and seven comparative oral antimicrobials were studied. MIC90S of cefixime were 0.015-1 micrograms/ml for Haemophilus influenzae, Branhamella catarrhalis, Escherichia coli, Klebsiella, Citrobacter diversus, Proteus, Providencia, Aeromonas hydrophila and Streptococcus. MIC90S for other Enterobacteriaceae were greater than or equal to 2 micrograms/ml; 44% of those strains were inhibited by less than or equal 1 microgram/ml. Staphylococcus, Psuedomonas aeruginosa and Enterococcus faecalis were resistant to cefixime.</p>","PeriodicalId":9733,"journal":{"name":"Chemioterapia : international journal of the Mediterranean Society of Chemotherapy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1988-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chemioterapia : international journal of the Mediterranean Society of Chemotherapy","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The in vitro activities of cefixime and seven comparative oral antimicrobials were studied. MIC90S of cefixime were 0.015-1 micrograms/ml for Haemophilus influenzae, Branhamella catarrhalis, Escherichia coli, Klebsiella, Citrobacter diversus, Proteus, Providencia, Aeromonas hydrophila and Streptococcus. MIC90S for other Enterobacteriaceae were greater than or equal to 2 micrograms/ml; 44% of those strains were inhibited by less than or equal 1 microgram/ml. Staphylococcus, Psuedomonas aeruginosa and Enterococcus faecalis were resistant to cefixime.
分享
京公网安备 11010802042870号
京ICP备2023020795号-1
求助内容：
应助结果提醒方式：
扫码关注我们
